JAK2 signaling can lead to phosphorylation and inactivation of the pro-apoptotic protein BAD via ERK, as well as AKT and PIM activity, which have also been investigated as therapeutic targets in MPN [48, 49, 51, 52, 58, 61]. This evidence concerns the gene AKT1 and myeloproliferative disorder.